# Aldeyra Therapeutics, Inc. (ALDX)

> Aldeyra Therapeutics, Inc. (ALDX) trades at $0.6305 (+0.06%) as of 5:22:57 AM EST on Nov 13, 2026, -20.28% over the past month. Market cap is $38.03M, with 3.4 days to cover in short interest.

Canonical: https://massive.com/quote/aldx
Data as of: 2026-11-13T10:22:57.201Z (15-minute delayed)
Source: Massive (https://massive.com/docs/llms.txt)

## Price

**$0.6305** +0.00 (+0.06%)
As of 5:22:57 AM EST on Nov 13, 2026 · 15-minute delayed
Nasdaq · usd

## Stock performance

How Aldeyra Therapeutics, Inc. (ALDX) stock has performed from one day to one year, with its 52-week range.

| Period | Return |
| --- | --- |
| 1D | -3.27% |
| 1W | +2.31% |
| 1M | -20.28% |
| YTD | -87.84% |
| 1Y | -87.52% |
| 52-wk range | $0.53 – $5.93 |

From daily closes through Nov 12, 2026.

## Key statistics

Today's trading snapshot for ALDX: day range, open, previous close, volume and market cap.

| Measure | Value |
| --- | --- |
| Day range | — |
| Open | — |
| Prev close | $0.63 |
| Volume | 0 |
| Market cap | $38.03M |
| Shares out | 60.33M |

## Valuation and profitability ratios

Valuation and profitability ratios for Aldeyra Therapeutics, Inc.: P/E, P/S, P/B, ROE and more.

| Measure | Value |
| --- | --- |
| P/E | — |
| P/S | — |
| P/B | 1.08 |
| P/FCF | — |
| ROE | -54.3% |
| ROA | -44.1% |
| Debt/Equity | 0.00 |
| Div yield | 0.00% |

As of Nov 12, 2026

## Insider trading

[Aldeyra Therapeutics, Inc. (ALDX) insider trading](https://massive.com/quote/aldx/insider-trading.md): open-market Form 4 buys and sells by Aldeyra Therapeutics, Inc. insiders over the last 12 months.

## 8-K filings

Material corporate events Aldeyra Therapeutics, Inc. has disclosed to the SEC on Form 8-K.

- Nov 9, 2026 · [Regulatory decision](https://massive.com/quote/sec-filings/8-k/regulatory-decisions.md)
  “In June 2023, we received a Complete Response Letter for our New Drug Application ("NDA") for ADX-2191 for the treatment of primary vitreoretinal lymphoma ("PVRL"), which stated that there was a lack of substantial evidence of effectiveness due to a lack of adequate and well-controlled investigations.”
- Sep 29, 2026 · Investor presentation
  “Aldeyra is holding a conference call regarding the announcement on September 29, 2026. A copy of the supplemental presentation, which will be referenced during the conference call and will be posted on Aldeyra's website is furnished herewith as Exhibit 99.1 and is incorporated by reference herein.”
- Jul 30, 2026 · Lease agreement
  “On July 28, 2026, Aldeyra Therapeutics, Inc. executed a lease agreement (the "Office Lease") with Bradford Street, L.L.C. for approximately 4,067 square feet of office space located at 23 Bradford Street, Concord, Massachusetts. The Office Lease commences on September 1, 2026 and the term with respect to the Premises shall be for a period ending on September 30, 2029. The Company intends to use the Premises as its corporate headquarters. The Office Lease provides for a monthly base rent of $12,201.00, increasing each year as indicated in the Office Lease.”
- Jul 15, 2026 · [Regulatory decision](https://massive.com/quote/sec-filings/8-k/regulatory-decisions.md)
  “On July 14, 2026, Aldeyra Therapeutics, Inc. (Aldeyra) received minutes (the Minutes) from a Type A meeting, held on June 10, 2026 with the U.S. Food and Drug Administration (FDA), regarding potential resubmission of the New Drug Application (NDA) of reproxalap for the treatment of dry eye disease.”
- Jun 10, 2026 · Annual meeting results
  “At the 2026 Annual Meeting held on June 9, 2026, the following proposals were submitted to the stockholders of the Company... The Company's stockholders elected the following director to serve as a Class III director until the 2029 annual meeting of stockholders... The Company's stockholders ratified the appointment of BDO USA, P.C. as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026... The Company's stockholders approved, on a non-binding, advisory basis, the compensation of the Company's named executive officers.”

## ALDX short interest

How heavily ALDX is shorted: shares short, days to cover and average daily volume.

| Measure | Value |
| --- | --- |
| Days to cover | 3.4 |
| Short interest | 3.16M |
| Avg volume | 917.9K |

As of Oct 30, 2026 · reported to FINRA twice monthly.

## ALDX news

The latest news and headlines about Aldeyra Therapeutics, Inc. (ALDX).

- [RARE's Fayuvi Approval Spurs Second PRV Sale Worth $203M in a Week](https://www.zacks.com/stock/news/3008649/rare-s-fayuvi-approval-spurs-second-prv-sale-worth-203m-in-a-week?cid=CS-ZC-FT-analyst_blog|company_news_medical_sector-3008649) · Zacks Investment Research · Oct 15, 2026 · positive sentiment
- [Here's Why You Should Add ANRO Stock to Your Portfolio Now](https://www.zacks.com/stock/news/3006998/here-s-why-you-should-add-anro-stock-to-your-portfolio-now?cid=CS-ZC-FT-analyst_blog|rank_focused-3006998) · Zacks Investment Research · Oct 14, 2026 · positive sentiment
- [Syndax Stock Falls 16% as Phase II Fibrosis Study Misses Primary Goal](https://www.zacks.com/stock/news/3006985/syndax-stock-falls-16-as-phase-ii-fibrosis-study-misses-primary-goal?cid=CS-ZC-FT-analyst_blog|company_news_medical_sector-3006985) · Zacks Investment Research · Oct 14, 2026 · negative sentiment
- [Prime Medicine Stock Rallies Nearly 26% in a Month: Here's Why](https://www.zacks.com/stock/news/3005327/prime-medicine-stock-rallies-nearly-26-in-a-month-here-s-why?cid=CS-ZC-FT-analyst_blog|price_surge_/_plunge-3005327) · Zacks Investment Research · Oct 12, 2026 · positive sentiment
- [PMVP Stock Rises 19% in 3 Months: Here's What You Need to Know](https://www.zacks.com/stock/news/3005238/pmvp-stock-rises-19-in-3-months-here-s-what-you-need-to-know?cid=CS-ZC-FT-analyst_blog|price_surge_/_plunge-3005238) · Zacks Investment Research · Oct 12, 2026 · positive sentiment

## About Aldeyra Therapeutics, Inc.

Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma, and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.

| Measure | Value |
| --- | --- |
| Exchange | Nasdaq |
| Market | stocks |
| Type | CS |
| Currency | USD |
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 6 |
| Listed | May 2, 2014 |

[Company website](https://www.aldeyra.com)

## FAQ

### What is the Aldeyra Therapeutics, Inc. (ALDX) stock price today?

Aldeyra Therapeutics, Inc. (ALDX) is trading at $0.6305 (+0.06% on the day) as of 5:22:57 AM EST on Nov 13, 2026. Prices are delayed at least 15 minutes; real-time quotes are available from the Massive API.

### What is Aldeyra Therapeutics, Inc.?

Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases.

### What is the short interest in ALDX?

As of Oct 30, 2026, ALDX has 3.16M shares short and 3.4 days to cover.

### What exchange is ALDX listed on?

Aldeyra Therapeutics, Inc. (ALDX) trades on Nasdaq in USD, in the PHARMACEUTICAL PREPARATIONS industry.

## Live data

Prices here are 15-minute delayed. For real-time ALDX quotes and the full history behind this page, use the Massive API or MCP server:

- `GET https://api.massive.com/v3/snapshot?ticker.any_of=ALDX`

Requests need a Massive API key. API reference for agents: https://massive.com/docs/llms.txt. Connect an AI agent through the Massive MCP server: https://massive.com/docs/ai-tools.

## Related

- [Aldeyra Therapeutics, Inc. (ALDX) insider trading](https://massive.com/quote/aldx/insider-trading.md)
- [SEC 8-K events](https://massive.com/quote/sec-filings/8-k.md)
- [Markets overview](https://massive.com/quote/index.md)

Nothing here is investment advice. Data and content are provided for informational purposes under the Massive Terms of Service: https://massive.com/terms
